Table 2.
Survey of herbal extracts compounds targeting the PI3K/AKT pathway for liver fibrosis alleviation.
| Compounds | In vitro activity | In vivo activity | Activity in human | References |
|---|---|---|---|---|
| Carthami flos extract (CFE) | Not assessed | Yes - mice | Not assessed | (98) |
| Esculetin | Not assessed | Yes - Wistar rats | Not assessed | (99) |
| 25-OCH3-PPD, a ginsenoside isolated from Panax ginseng | Not assessed | Yes - mice | Not assessed | (100) |
| Cichorium pumilum Jacq extract (CGEA) | Yes - RAW264.7 cells. | Yes - rats | Not assessed | (70) |
| Tanshinone IIA (TIIA) | Yes - HSC-LX2 | Yes - rats | Not assessed | (101) |
| Luteolin | Yes - HSCs and HSC- T6 Cell | Yes - mice Sprague–Dawley rats | Not assessed | (102) |
| Naringin | Not assessed | Yes - rat | Not assessed | (103) |
| Aronia melanocarpa polysaccharide (AMP) | Not assessed | Yes - TAA-induced liver fibrosis mice | Not assessed | (53) |
| Lycopene | Not assessed | Yes - rats | Not assessed | (104) |